These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34235677)

  • 1. Drug Sensitivity Testing of Mycobacterium tuberculosis Growing in a Hollow Fiber Bioreactor.
    Mason AB; Dartois V
    Methods Mol Biol; 2021; 2314():715-731. PubMed ID: 34235677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Cavaleri M; Manolis E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
    Gumbo T; Pasipanodya JG; Romero K; Hanna D; Nuermberger E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S25-31. PubMed ID: 26224769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.
    Gumbo T; Angulo-Barturen I; Ferrer-Bazaga S
    J Infect Dis; 2015 Jun; 211 Suppl 3():S96-S106. PubMed ID: 26009618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
    Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
    Romero K; Clay R; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S5-9. PubMed ID: 26224771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
    Vaddady PK; Lee RE; Meibohm B
    Future Med Chem; 2010 Aug; 2(8):1355-69. PubMed ID: 21359155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.
    Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S267-S273. PubMed ID: 30496455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Moxifloxacin against
    Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
    Drusano GL; Duncanson B; Scanga CA; Kim S; Schmidt S; Neely MN; Yamada WM; Vicchiarelli M; Peloquin CA; Louie A
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
    Davies GR; Nuermberger EL
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S65-74. PubMed ID: 18762154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.
    Bax HI; Bakker-Woudenberg IAJM; de Vogel CP; van der Meijden A; Verbon A; de Steenwinkel JEM
    Tuberculosis (Edinb); 2017 Jul; 105():80-85. PubMed ID: 28610791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.
    Drusano GL; Myrick J; Maynard M; Nole J; Duncanson B; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Louie A
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
    Christophe T; Ewann F; Jeon HK; Cechetto J; Brodin P
    Future Med Chem; 2010 Aug; 2(8):1283-93. PubMed ID: 21426019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More than cholesterol catabolism: regulatory vulnerabilities in Mycobacterium tuberculosis.
    Bonds AC; Sampson NS
    Curr Opin Chem Biol; 2018 Jun; 44():39-46. PubMed ID: 29906645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico approaches and chemical space of anti-P-type ATPase compounds for discovering new antituberculous drugs.
    Santos P; López-Vallejo F; Soto CY
    Chem Biol Drug Des; 2017 Aug; 90(2):175-187. PubMed ID: 28111912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.